SCHEMBL5544707

SCHEMBL5544707

Cc1cccc(N([C]=O)Cc2ccccc2)c1C

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.44
ALDH1A1 P00352 5/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 3/20 0.42
MAPK1 P28482 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
NR3C1 P04150 6/20 0.40
PGR P06401 1/20 0.40
NR3C2 P08235 1/20 0.40
AR P10275 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.38
ALOX12 P18054 1/20 0.37
HTT P42858 1/20 0.37
TEAD1 P28347 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2095694 0.88 TRPM8 (0.51) TRPM8ALDH1A1KMT2ALMNATSHR
SCHEMBL2097526 0.84 MEN1 (0.46) TRPM8ALDH1A1KMT2AMEN1LMNA
SCHEMBL2098168 0.84 KDM4E (0.44) TRPM8ALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL22188466 0.78 NR3C1 (0.56) TRPM8NR3C1PGRNR3C2AR
Bicarbonate SCHEMBL22188468 0.75 NR3C1 (0.55) TRPM8ALDH1A1KMT2AMEN1LMNA
SCHEMBL2095513 0.75 HPGD (0.41) TRPM8ALDH1A1KMT2AMEN1LMNA
SCHEMBL2096127 0.75 MEN1 (0.41) TRPM8ALDH1A1KMT2AMEN1LMNA
SCHEMBL2093787 0.75 TDP1 (0.44) ALDH1A1KMT2AMEN1TSHRSMN1; SMN2
SCHEMBL2097135 0.75 ALDH1A1 (0.37) TRPM8ALDH1A1KMT2AMEN1LMNA
Oxalic Acid SCHEMBL22188502 0.74 NR3C1 (0.54) TRPM8ALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TRPM8 3538/4885ALDH1A1 355/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.